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Abstract
Trypanosoma brucei gambiense causes 97% of all cases of African sleeping sickness, a fatal disease of sub-Saharan Africa.
Most species of trypanosome, such as T. b. brucei, are unable to infect humans due to the trypanolytic serum protein
apolipoprotein-L1 (APOL1) delivered via two trypanosome lytic factors (TLF-1 and TLF-2). Understanding how T. b.
gambiense overcomes these factors and infects humans is of major importance in the fight against this disease. Previous
work indicated that a failure to take up TLF-1 in T. b. gambiense contributes to resistance to TLF-1, although another
mechanism is required to overcome TLF-2. Here, we have examined a T. b. gambiense specific gene, TgsGP, which had
previously been suggested, but not shown, to be involved in serum resistance. We show that TgsGP is essential for
resistance to lysis as deletion of TgsGP in T. b. gambiense renders the parasites sensitive to human serum and recombinant
APOL1. Deletion of TgsGP in T. b. gambiensemodified to uptake TLF-1 showed sensitivity to TLF-1, APOL1 and human serum.
Reintroducing TgsGP into knockout parasite lines restored resistance. We conclude that TgsGP is essential for human serum
resistance in T. b. gambiense.
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Introduction
Throughout their evolution in sub-Saharan Africa, humans
have been under assault by a range of different pathogens. One
defining challenge is that posed by African trypanosomes, a species
complex of blood-borne protozoan parasites transmitted by tsetse
flies [1]. The principle pathogenic species in Africa are Trypanosoma
brucei, T. congolense and T. vivax, although only Trypanosoma brucei
sub-species are able to infect humans. A key feature of these
parasites is the ability to undergo antigenic variation by modifying
the variant specific glycoprotein (VSG) enveloping the cell that
renders the mammalian adaptive immune system largely ineffec-
tive [2]. Components of the innate immune system therefore
contribute significantly to defence against these organisms [3].
Critical to these defences is the serum protein apolipoprotein L1
(APOL1) found in some catarrhine primates, including humans
[4,5]. The protein is able to kill the majority of trypanosome
species in a dose-dependent manner [5]. APOL1 is delivered to
parasites in two fractions of the high-density lipoprotein (HDL)
component of serum, termed trypanolytic factor 1 and 2 (TLF-1
and TLF-2) [6]. TLF-1 binds to the parasite through an
interaction between the haptoglobin-related protein (HPR)
surrounding the TLF-1 particle and the haptoglobin haemoglobin
receptor (HpHbR) in the flagellar pocket of the parasite [7–9].
Under the acidic conditions found in the lysosome, APOL1
changes conformation and embeds in the lysosomal membrane,
forming pores in the organelle, leading to cell death [5,10]. A
proportion of TLF-2 similarly enters trypanosomes via HpHbR,
although an alternate route also contributes to uptake [11].
Although TLF-1 and 2 kill the majority of trypanosome species,
two sub-species of T. brucei have evolved to overcome this innate
immunity. T. b. rhodesiense and T. b. gambiense are both resistant to
lysis by APOL1 and establish bloodstream infections in humans
[1]. T. b. rhodesiense causes an acute form of the disease and is found
in East Africa whereas T. b. gambiense is found in West and Central
Africa. T. b. gambiense causes a more chronic form of the disease
and is responsible for 97% of all human cases of trypanosomiasis
[12]. The mechanism of human serum resistance for T. b.
rhodesiense involves the expression of a truncated VSG, termed
serum resistance associated (SRA) protein [13,14]. SRA binds to
APOL1 in the lysosome, preventing lysis [14]. However, the SRA
gene is absent from T. b. gambiense, the more prevalent human
infective sub-species [15]. The T. b. gambiense subspecies consists of
two sub-groups (1 and 2) that differ in phenotype, including their
associated pathology. Group 1 T. b. gambiense parasites are the most
prevalent of the human infective trypanosomes and are responsible
for the vast majority of cases [16]. Group 1 T. b. gambiense can be
distinguished by both their reduced efficacy of HpHbR for binding
TLF-1, due to a conserved single nucleotide polymorphism [17–
19] and also by the presence of a specific truncated VSG, TgsGP
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[20]. The TgsGP gene is present in all group 1 isolates examined to
date but not in T. b. brucei, T. b. rhodesiense or group 2 T. b. gambiense
[20–23]. The specificity of TgsGP to group 1 T. b. gambiense and its
resemblance to SRA, in that it is a truncated VSG gene, led to a
suggestion that this gene may confer human serum resistance to
group 1 T. b. gambiense [20]. The gene was transfected into T. b.
brucei where it did not confer increased resistance to human serum.
It was hypothesized that if TgsGP was involved in human serum
resistance other factors would also be required to confer the
phenotype in T. b. brucei [20]. Efforts to delete the gene from T. b.
gambiense were unsuccessful and the function of TgsGP remained
unknown [20]. Here we have successfully deleted the TgsGP gene
from T. b. gambiense and demonstrated that it is essential for human
serum resistance and requires a T. b. gambiense genetic background
in order to function.
Results
Deletion of TgsGP in wild-type group 1 T. b. gambiense
To assess whether TgsGP is involved in human serum resistance
in T. b. gambiense, the gene was deleted from the genome of a group
1 T. b. gambiense strain. All strains of T. b. gambiense investigated so
far are hemizygous for TgsGP, allowing a complete knockout with
just one round of transfection [20–22]. Although it was postulated
that TgsGP was an essential gene and could not be deleted [20],
several TgsGP2/0 clones were generated in this study. One of the
clones was selected for analysis and used for subsequent assays.
The deletion of TgsGP from the clone was confirmed by PCR
(Figure 1A). The TgsGP2/0 T. b. gambiense clones was unable to
survive in the presence of normal human serum (Figure 2) or
recombinant APOL1 (Figure 2), with significantly fewer surviving
cells compared to wild-type T. b. gambiense (human serum t-test
p = 0.001, APOL1 t-test p,0.001). The clone grew in the presence
of non-lytic serum in a similar manner to wild-type T. b. gambiense
(t-test p = 0.145). This indicates that TgsGP is involved in
protecting against the trypanolytic protein APOL1.
The clone was able to grow in the presence of TLF-1 and the
number of cells after 24 hours does not differ significantly from
that of the wild-type T. b. gambiense strain (t-test p = 0.511). Wild-
type T. b. gambiense is resistant to lysis by TLF-1 due to reduced
efficacy of their HpHbR for binding TLF-1. Thus lethal amounts
of the lytic particle are not internalised by the parasites [18,19]. It
is likely that TgsGP2/0 T. b. gambiense clones are able to grow in the
presence of TLF-1 because it possesses the T. b. gambiense HpHbR
allele that is less efficient at binding TLF-1.
Deletion and reintroduction of TgsGP in TbbHpHbR2/+ T.
b. gambiense
As previously detailed, group 1 T. b. gambiense is characterised by
a non-functional HpHbR which results in a reduced uptake of
TLF-1 and to a lesser extent TLF-2 [17–19,24]. To investigate the
effect of the loss of TgsGP in combination with TLF-1 uptake, a T.
b. gambiense strain expressing a functional T. b. brucei HpHbR
(TbbHpHbR) and lacking TgsGP was created (termed TbbHpHbR2/
+ TgsGP2/0). Expression of both wild-type and ectopic TbbHpHbR
alleles was confirmed by RT-PCR (Figure 1B). An allele-specific
HpyCh4V restriction site present in the open reading frame of
TbbHpHbR, but absent in TbgHpHbR, was used to distinguish
between the alleles (Figure 1B) and demonstrated that both alleles
were expressed, although the TbgHpHbR allele exhibits lower
expression relative to the TbbHpHbR allele. The strain expresses a
fully functional HpHbR and hence takes up TLF-1 to a degree
similar to T. b. brucei, confirmed by fluorescence microscopy
(Figure 3). TbbHpHbR2/+ TgsGP2/0 T. b. gambiense clones were
killed in the presence of normal human serum, recombinant
APOL1 or, unlike TgsGP2/0 clones, physiological levels of TLF-1
(Figure 2). The number of remaining cells at 24 hours was
significantly lower than wild-type T. b. gambiense (human serum t-
test p= 0.001, TLF-1 t-test p,0.001, APOL1 t-test p,0.001).
However, the cells were able to grow in the presence of non-lytic
serum in a similar manner to wild-type T. b. gambiense (t-
test = 0.690). A T. b. gambiense clone with TgsGP and the functional
TbbHpHbR was able to grow in the presence of human serum and
APOL1 (Figure 2) with cell number not significantly differing from
wild-type T. b. gambiense (human serum t-test p= 0.936, APOL1 t-
test p= 0.465) or in the presence of non-lytic serum (t-test
p = 0.972). However, the clone displayed a trypanostatic growth
effect in physiological levels of purified TLF-1 with significantly
fewer surviving cells compared to wild type (Figure 2) (t-test
p = 0.001).
To confirm that the loss of resistance to human serum, APOL1
and TLF-1 in TbbHpHbR2/+ TgsGP2/0 T. b. gambiense was due to
the loss of TgsGP, the gene was re-introduced into this background.
Resistance to human serum, TLF-1 and APOL1 was rescued by
the re-introduction of TgsGP, confirming that this gene is essential
for resistance to lysis (Figure 2). When the same TgsGP add-back
construct was transfected into a human serum sensitive T. b. brucei,
it did not confer resistance to any lytic component (Figure 2),
confirming earlier work [20].
Localisation of TgsGP
Previous work has shown that TgsGP localises to the flagellar
pocket in T. b. gambiense and this is likely to be the site of interaction
between TLF and TgsGP [20]. A possible hypothesis for the
observation that when TgsGP is transfected into in TbbHpHbR2/+
TgsGP2/0 T. b. gambiense background it restores human serum
resistance but does not confer resistance in T. b. brucei [20] (figure 2)
is that the protein is not trafficked correctly to the flagellar pocket. In
order to verify localisation, TgsGP was transfected into wild-type T.
b. brucei with the addition of a TY tag into aHindIII restriction site at
position 1130 of the TgsGP ORF, upstream of the predicted GPI
anchor sequence [25,26]. Immunofluorescence with anti-TY
antibodies shows clear localisation of TY-TgsGP adjacent to the
kinetoplast and co-localization with fluorescent Concanavalin A,
Author Summary
Trypanosoma brucei gambiense causes 97% of all cases of
African sleeping sickness, a fatal disease of sub-Saharan
Africa. Most species of trypanosome, such as T. b. brucei,
are unable to infect humans due to trypanolytic factors in
human serum. Understanding how T. b. gambiense
overcomes these factors and infects humans is of major
importance in the fight against this disease. Previous work
indicated that a failure to take up some trypanolytic factors
by T. b. gambiense contributes to resistance, although
other mechanisms are involved. Here, we have examined a
T. b. gambiense specific gene, TgsGP, for involvement in
resistance to human serum. We show that TgsGP is
essential for resistance to lysis as deletion of TgsGP in T.
b. gambiense renders the parasites sensitive to most
trypanolytic factors. TgsGP deletion in T. b. gambiense
modified to overcome the sub-species trait to reduce
uptake of some trypanolytic factors resulted in sensitivity
to all trypanolytic factors. Reintroducing TgsGP into these
knockout parasite lines restored resistance. We conclude
that TgsGP is essential for human serum resistance in T. b.
gambiense.
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which acts as a marker for the flagellar pocket [27], (Figure 4).
However, these cells were killed in human serum, TLF-1 or APOL1
(Figure S1). A similar localisation is observed when the TY-tagged
TgsGP protein is expressed in TbbHpHbR2/+ TgsGP2/0 T. b.
gambiense (Figure 4), with strong signal close to the kinetoplast and a
more diffuse signal closer to the nucleus. In this case, the capacity to
grow in human serum, TLF-1 and APOL1 was restored by the
reintroduction of the TY-tagged TgsGP (Figure S1). As an identical
construct was used in both transfections, it is probable that group 1
T. b. gambiense possess a protein or mechanism complementing
TgsGP that is absent in T. b. brucei.
Discussion
This study demonstrates that the TgsGP gene is essential for
resistance to human serum in the most clinically important T.
brucei sub-species, group 1 T. b. gambiense. Previous work has shown
that TgsGP did not confer resistance to human serum when
ectopically expressed in T. b. brucei [20], which was confirmed
here. As originally hypothesized [20], it appears likely that this is
due to other factor(s) or mechanism(s) that works in concert with
TgsGP, which are absent in T. b. brucei. By removing TgsGP from
T. b. gambiense itself, we have demonstrated that the gene is
necessary for resistance to human serum. Elucidation of a gene
essential to human serum resistance in group 1 T. b gambiense
unlocks new avenues for future treatment of human African
sleeping sickness. These include peptide screens that neutralise the
TgsGP protein, targeted antibodies or the possibility of using
TgsGP as a vaccine candidate, as expression is required for
parasite survival in humans. Additionally, there exists the potential
that variants of APOL1 may offer protection against T. b.
gambiense. Sera from individuals possessing certain APOL1 alleles
has been shown to affect the growth of T. b. rhodesiense and it has
been suggested that these alleles may be protective against T. b.
Figure 1. PCR amplification of TgsGP and RT-PCR of HpHbR in wild-type and transfected lines. (A) Amplification of TgsGP and a control
gene (cathepsin L) by PCR in [1] wild-type T. b. brucei [2], TgsGP2/+ T. b. brucei [3], wild-type T. b. gambiense, [4] TgsGP2/0 T. b. gambiense [5] and
negative control. (B) RT-PCR amplification of HpHbR followed by HpyCH4V restriction digestion of [1] wild-type T. b. brucei, [2] wild-type T. b.
gambiense and [3] TbbHbHpR2/+TgsGP2/0 T. b. gambiense.
doi:10.1371/journal.ppat.1003686.g001
Figure 2. TgsGP is essential for resistance to human serum in T. b. gambiense. The number of surviving cells after 24 hours incubation with
20% human serum (open box), 10 mg/ml TLF-1 (dark grey box), 50 mg/ml recombinant APOL1 (light grey box) or a non-lytic 20% FBS control (black
box). The dotted line indicates the starting concentration of 56105 cells. The cell lines assayed were wild-type T. b. brucei; TgsGP2/+ T. b. brucei; wild-
type T. b. gambiense; TgsGP2/0 T. b. gambiense; TbbHbHpR2/+ T. b. gambiense; TbbHbHpR2/+ TgsGP2/0 T. b. gambiense and TbbHbHpR2/+ TgsGP2/+ T. b.
gambiense. Standard error is shown, n = 4 for each data point.
doi:10.1371/journal.ppat.1003686.g002
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rhodesiense [28,29]. However, this has yet to be confirmed in a case
control study. Nevertheless, it is likely that there are variant
APOL1 alleles that protect against group 1 T. b. gambiense in
resistant individuals, such as the reportedly resistant Bambuti
people of the Mbomo region in the Democratic Republic of the
Congo [30] or recently described asymptomatic and self-cured
cases from Coˆte d’Ivoire [31].
One other benefit of our study is the trypanosome research
community now possesses a representative group 1 T. b. gambiense
strain that is easily cultured, is no longer human serum resistant,
yet only differs from the wild-type by a single gene. This is a
powerful biological resource that could replace T. b. brucei as the
common laboratory model for the human disease, which maybe
useful, particularly as several drugs display different efficacies
between sub-species [1]. As such, identifying TgsGP as a gene
essential for resistance to human serum in group 1 T. b. gambiense
will likely be important to future control of the disease.
Materials and Methods
Trypanosomes strains and maintenance
Bloodstream form T. b. brucei Lister 427 (MITat 1.2) was grown
at 37uC under 5% CO2 in HMI9 medium supplemented with
20% foetal bovine serum (Sigma-Aldrich) and 20% Serum-Plus
Figure 3. Uptake of TLF-1 across strains. Uptake of TLF-1 after one hour in [1] wild-type T. b. brucei [2] wild-type T. b. gambiense and [3]
TbbHbHpR2/+ TgsGP2/0 T. b. gambiense by co-localization of fluorescently tagged TLF-1 (green) with the lysosomal marker Lysotracker (red). The
kinetoplast and nucleus were also stained using DAPI (blue).
doi:10.1371/journal.ppat.1003686.g003
Figure 4. Localisation of TY-TgsGP. Localisation of TY-tagged TgsGP (red) relative to un-endocytosed FITC-labeled Concanavalin A bound to
glycoproteins in the flagellar pocket (green) and DAPI stained nucleus and kinetoplast (blue) in [1] TY-TgsGP2/+ T. b. brucei and [2] TbbHbHpR2/+ TY-
TgsGP2/+ T. b. gambiense. The flagellar pocket (revealed by Concanavalin A and kinetoplast position) is indicated with a white arrow.
doi:10.1371/journal.ppat.1003686.g004
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(Sigma-Aldrich). The bloodstream form group 1 T. b. gambiense
strain ELIANE (MHOM/CI/52/ELIANE) was isolated from a
patient infected while in Coˆte d’Ivoire [22]. It was cultured in
modified HMI9 [32] supplemented with 20% serum plus (SAFC
Biosciences Ltd.). Similar to other group 1 T. b. gambiense strains,
ELIANE is consistently resistant to lysis by human serum, despite
repeated passage.
Transfection of T. b. brucei and group 1 T. b. gambiense
T. b. gambiense and T. brucei strains were transfected using the
protocols outlined in [33]. For ectopic expression of TgsGP in T. b.
brucei and reinsertion into the TgsGP2/0 T. b. gambiense strains, the
TgsGP ORF was inserted into the pURAN vector [34] using G418
for selection. Ectopic expression of TbbHbHpR in T. b. gambiense
was achieved using the tubulin-targeting TbbHbHpR pTub-phelo
construct, using phleomycin for selection [17]. For deletion of
TgsGP from the genome of T. b. gambiense and TbbHbHpR2/+T. b.
gambiense, 500 base pairs from both the upstream and downstream
regions of TgsGP (sequence AM237444.1, http://www.genedb.
org) were inserted into a vector containing a hygromycin resistance
cassette. Insertion of TY-tagged TgsGP into the deletion strain T. b.
gambiense and T. b. brucei was performed by inserting a TY tag into
a HindIII restriction site at position 1130 of the TgsGP ORF. This
sequence was ligated into the pURAN vector [34,35] and
transfectants were screened using a G418 selection marker. This
insertion site is upstream of the predicted GPI anchor site
identified using the big-PI software package [25] and a GPI
prediction protocol validated for trypanosomes [26]. Correct
integration for constructs was assessed by PCR and/or RT-PCR.
All primers used in the studies and their targets, are listed in Table
S1.
RT-PCR of expressed TbbHpHbR in group 1 T. b.
gambiense
Total RNA was isolated from cells using RNeasy kit (Qiagen)
according to manufacturers’ instruction, with additional DNase
steps. 2 mg RNA was subject to a second round of DNase
treatment (Invitrogen) prior to cDNA synthesis using Superscript
III (Invitrogen), according to manufacturers’ instructions. RT-
PCR was performed using Taq DNA polymerase and the primers
are described in Table S1. For RFLP analysis of HpHpR, the
amplified product was cleaned using GeneJet PCR purification
column, digested with HpyCh4V and the digested products
separated on a 2% agarose gel.
TLF-1 purification
TLF-1 purification, labeling and survival assays were performed
as previously described [17,36].
Generation of recombinant APOL1
APOL1 synthesis and purification was performed as previously
described [36]. Protein purity was estimated using a Nanodrop
spectrometer (Nanodrop) and SDS-PAGE. A Western blot using
an antibody raised against an APOL1 peptide (Sigma-Aldrich) was
used to verify that the bands present were APOL1.
Lysis survival assays
To assess survival in human serum, trypanosomes were diluted
to 56105 per ml in HMI9 and incubated for 24 hours with 20%
human serum or 20% non-lytic foetal bovine serum (FBS). The
number of surviving trypanosomes in each well was recorded after
24 hours using a haemocytometer. To assess survival in TLF-1
and APOL1, trypanosomes were diluted to 56105 per ml in HMI9
with FBS. Cells were incubated with a physiological amount of
TLF-1 (10 mg/ml). For the recombinant APOL1 assays, a
concentration of 50 mg21 ml was used as this had previously been
determined to kill 100% of T. b. brucei cells in a 24-hour assay [36].
The number of cells in each well was counted with a
haemocytometer at 24 hours. There were four replicates for each
data point. The number of surviving cells for each treatment were
compared between each of the T. b. gambiense clones and wild-type
T. b. gambiense using the unpaired 2-tailed t-test function of the
Minitab 14 Statistics Package (Minitab).
Immunofluorescence assays
TLF-1 immunofluorescence assays were performed as previ-
ously described [17,36]. Immunofluorescence localisation of TY-
TgsGP was performed with approximately 106 bloodstream-
cultured parasites in mid-log phase. Cells were incubated with
5 mg/ml FITC conjugated Concanavalin A in serum-free HMI9
for 20 minutes at 4uC. The Concanavalin A binds to glycoproteins
in the flagellar pocket but is not endocytosed due to the reduced
temperature, thus labeling the flagellar pocket [27]. Cells were
then fixed by immersion in chilled methanol for 30 minutes. Slides
were incubated for 1 hour with 1:500 primary mouse anti-TY
antibody (Iain Johnston, University of Glasgow), washed with PBS
and then incubated with 1:1000 of AlexaFluor568 anti-mouse
secondary (Invitrogen). The slides were mounted using 50%
glycerol, 0.1% DAPI and 2.5% DABCO. Parasites were imaged
using a Deltavision Core system and SoftWorx package (Applied
Precision). Images were composited using the ImageJ software
package [37].
Supporting Information
Figure S1 TY-TgsGP behaves similarly to TgsGP. The
number of surviving cells after 24 hours incubation with 20%
human serum (open box), 10 mg/ml TLF-1 (dark grey box),
50 mg/ml recombinant APOL1 (light grey box) or a non-lytic 20%
FBS control (black box). The dotted line indicates the starting
concentration of 56105 cells. The cell lines assayed were TY-
TgsGP2/+ T. b. brucei and TbbHbHpR2/+ TY-TgsGP2/0 T. b.
gambiense. Standard error is shown, n= 2 for each data point.
(DOCX)
Table S1 Primers used and their function.
(DOCX)
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